In a DCIS-like mouse xenograft study, daily oral AZD6244 (16 mg/kg) produced reported growth inhibition >75% in 14-3-3ζ-overexpressing tumors and <50% in empty-vector tumors versus their respective vehicle controls (5 mice/group). These are model-specific growth effects. [1]
Responses varied across pediatric xenografts. The primary PPTP panel had no objective responses, and deaths occurred in 11/428 treated mice versus 0/420 controls. In subsequent astrocytoma tests, BT-40 tumors (BRAF V600E) completely regressed during treatment, whereas BT-35 tumors (BRAF wild type) progressed; BT-40 regrowth followed withdrawal. [2]
DCIS-like mammary xenograft growth
Animal study · MCF10DCIS.COM.ζ and empty-vector DCIS.COM.Vec orthotopic mammary tumors in 6-week-old female SWISS nu/nu mice [1]
Daily AZD6244 inhibited growth of both tumor variants, with a larger reported inhibition in 14-3-3ζ-overexpressing tumors. The Ki-67 reduction was significant in the ζ tumors; the vector comparison was not marked significant. Groups contained 5 mice.
Conditions shared by the study groups
- Route
- Oral gavage
- Frequency
- Daily
- Treatment course
- Day 10 to day 30 after implantation; 20 days after treatment initiation
- Vehicle
- 0.5% HPMC, 0.1% Tween 80 in 25 mM citrate
- 14-3-3ζ-overexpressing tumors
- Model: DCIS.COM.ζ mammary xenografts
- Reported limits: No per-experiment vendor/lot; salt unspecified.
- Empty-vector tumors
- Model: DCIS.COM.Vec mammary xenografts
- Reported limits: No per-experiment vendor/lot; salt unspecified.
Methods and source locations
Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244
Compound-level relevance; does not validate an Adooq lot or establish supplier-specific performance or salt equivalence.
Figure 5A–D; Results: targeting MEK/ERK/CREB; Methods: tumor xenograft studies
Tumor growth versus respective vehicle-treated model: Serial caliper measurements; relative tumor volume — Results: targeting MEK/ERK/CREB paragraph corresponding to Figure 5B
14-3-3ζ-overexpressing tumors · Figure 5A–D; corresponding Results; tumor xenograft methods
Empty-vector tumors · Figure 5A–D; corresponding Results; tumor xenograft methods
Limited responses in the primary pediatric xenograft panel
Animal study · Primary PPTP panel: 44 xenograft models tested; 43 evaluable after exclusion of ALL-17 for >25% toxicity [2]
No objective responses (defined in the main text as ≥50% tumor-volume regression) were reported. Ten of 43 evaluable models had significant EFS-distribution differences. Eleven of 428 treated mice died versus 0 of 420 controls; one model was excluded for toxicity. P values were exploratory and unadjusted for multiple comparisons.
Conditions shared by the study groups
- Route
- Oral (p.o.)
- Frequency
- Twice daily Monday–Friday; once daily Saturday–Sunday
- Treatment course
- 6 consecutive weeks
- Vehicle
- 0.5% hydroxypropyl methyl cellulose, 0.1% Polysorbate 80
- Primary panel AZD6244
- Model: PPTP primary xenograft panel; 10 mice/group for solid tumors and 8/group for ALL, before exclusions
- Reported limits: Detailed schedule conflicts with simplified abstract; supplemental response definitions and full exclusion table were not retrieved.
Methods and source locations
Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244
Research compound evidence; no Adooq material validation or conversion to a sulfate formulation.
Results: in vivo testing; Table II; Figure 2; Drugs and Formulation; Figure 3 caption
Objective response in primary evaluable panel: Main Results define objective responses as ≥50% tumor-volume regression; Figure 2 group response classification — Results: in vivo testing; Figure 2
Deaths during primary panel study: Author-reported deaths during study; not assumed all drug-caused — Results: in vivo testing opening paragraph
Primary panel AZD6244 · Drugs and Formulation; Figure 3 caption; Results in vivo testing; Figure 2
Contrasting responses of BT-35 and BT-40 astrocytoma xenografts
Animal study · BT-35 (BRAF wild type) and BT-40 (BRAF V600E) juvenile pilocytic astrocytoma xenografts [2]
BT-40 showed complete regressions at the end of six weeks across the reported schedules, whereas BT-35 progressed. Regrowth after treatment withdrawal depended on cumulative exposure. These two models do not establish BRAF genotype as a sufficient predictor across cancers.
Conditions shared by the study groups
- Route
- Oral (p.o.)
- Frequency
- Twice daily Monday–Friday; once daily Saturday–Sunday
- Treatment course
- 6 consecutive weeks
- Vehicle
- 0.5% hydroxypropyl methyl cellulose, 0.1% Polysorbate 80
- BT-35 comparator
- Model: BT-35; BRAF wild type
- Reported limits: Secondary cohort-specific n and exclusions not retrieved; genotype comparison is between different tumor models, not an isogenic test.
- BT-40 responsive model
- Model: BT-40; BRAF V600E
- Reported limits: Secondary cohort-specific n and exclusions not retrieved; genotype comparison is between different tumor models, not an isogenic test.
Methods and source locations
Compound reported in the paper: Selumetinib; Compound label in the paper: AZD6244
Research compound evidence; no Adooq material validation or conversion to a sulfate formulation.
Results: JPA xenografts; Figure 7A–B and caption; Drugs and Formulation
End-of-treatment tumor response: Tumor-volume trajectories and author-reported response — JPA Results and Figure 7A–B
BT-35 comparator · Figure 7A–B and caption; JPA Results; Drugs and Formulation
BT-40 responsive model · Figure 7A–B and caption; JPA Results; Drugs and Formulation